05 July 2019
Carl Zeiss Meditec has become a shareholder of Minneapolis-based minimally invasive glaucoma surgery (MIGS) company MicroOptx Inc.
MicroOptx Inc’s technology is designed to provide effective reduction of intraocular pressure through a simple surgical procedure. Its Brown Glaucoma Implant shunts aqueous humour to the tear film.
Carl Zeiss Meditec explained that it believes MicroOptx Inc’s MIGS solution will complement its own portfolio of ophthalmic surgery equipment.
Global president of ophthalmic devices at Carl Zeiss Meditec, James Mazzo, said: “The investment in MicroOptx will give Zeiss an early position in this new technology designed to increase MIGS adoptions for treating glaucoma.”
MicroOptx Inc’s technology is designed to provide effective reduction of intraocular pressure through a simple surgical procedure. Its Brown Glaucoma Implant shunts aqueous humour to the tear film.
Carl Zeiss Meditec explained that it believes MicroOptx Inc’s MIGS solution will complement its own portfolio of ophthalmic surgery equipment.
Global president of ophthalmic devices at Carl Zeiss Meditec, James Mazzo, said: “The investment in MicroOptx will give Zeiss an early position in this new technology designed to increase MIGS adoptions for treating glaucoma.”
Comments (0)
You must be logged in to join the discussion. Log in